Unlike in the rest of the country, where intestinal ultrasound rarely is used in the clinic, in New York City, gastroenterologists at Mount Sinai Hospital have made IUS findings the “the fifth vital sign” for inflammatory bowel disease patient care, particularly to monitor disease. Now, new research from the institution and other centers is showing that the tool can identify patients with endoscopic recurrence and possibly predict disease outcomes and treatment response.
Trending
- 5 doctors weigh in on the promise, limitations of Grail’s multicancer test (Medtech Dive)
- IBS Pain Closely Linked to Interrelated Daily-Life Triggers (Physicians Weekly)
- First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication (Takeda)
- Industry Voices—How physician practices can grow and succeed without the support of private equity (Fierce Healthcare)
- Blood-Based CRC Test Upgrades Improve on Precancerous Lesion Detection (Medscape)
- Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing (Lucid Diagnostics)
- How Can GI Fellowship Programs Enhance Ambulatory Training? (Yale School of Medicine)
- VIOVOC Issued U.S. Patent for Ambient Sensing Technology That Decodes Gut Microbiome Signals (Business Wire)
